Isolation, characterization and genomic insights of the lytic bacteriophage TANUVAS_MVC-VPH-AB targeting Acinetobacter spp. with antibacterial and anti-biofilm activity.

backgroundAcinetobacter baumannii, is a WHO-recognized critical pathogen, poses a severe clinical threat due to multidrug resistance, environmental persistence and a robust biofilm formation. The rapid failure of conventional antibiotics necessitates alternative strategies, with bacteriophage therapy emerging as a promising, targeted, and eco-friendly approach. METHODS AND

resultsIn this study, a lytic bacteriophage, designated TANUVAS_MVC-VPH-AB, was isolated and characterized for its activity against Acinetobacter spp. Morphological and genomic analyses classified the phage within the class Caudoviricetes, possessing a linear double-stranded DNA genome of 45 kb and a GC content of 37.61%. Genome annotation identified 93 putative genes, with no virulence-associated genes and antibiotic resistance determinants supporting its safety as a potential therapeutic agent. The phage demonstrated strong lytic activity and a restricted yet polyvalent host range within the A. calcoaceticus - A. baumannii complex, along with detectable stability across the tested pH and temperature conditions. Additionally, it demonstrated potent biofilm inhibition and eradication on abiotic surfaces (polystyrene).

conclusionThese findings suggest that TANUVAS_MVC-VPH-AB is a promising candidate for bacteriophage therapy, offering a viable alternative to combat MDR A. baumannii infections, particularly in biofilm-associated environments within hospital and food related settings.